Skip to main content
. Author manuscript; available in PMC: 2013 Sep 1.
Published in final edited form as: Mol Cancer Ther. 2012 Jun 29;11(9):1852–1862. doi: 10.1158/1535-7163.MCT-12-0181

Figure 6.

Figure 6

In vivo studies. Inhibition of tumor size and weights (A), H&E and Sp1, Sp3 and Sp4 staining (B), and miR-106b/miR-92 levels (C) in mice treated with CDODA-Me. Athymic nude mice bearing PC3 cells as xenografts were treated with CDODA-Me (15 mg/kg/d) over a period of 21 days, and tumor volumes were estimated. Tumor weights, H&E and Sp1 staining, and miR mRNA levels were determined as outlined in the Materials and Methods. (D) Mode of action for CDODA-Me. Proposed pathways triggered by CDODA-Me in prostate cancer cells/tumors that lead to downregulation of Sp1, Sp3, Sp4 and Sp-regulated genes/responses. Results are expressed as means ± SE for at least three replication determinations, and significantly (p < 0.05) decreased (*) responses are indicated.